scispace - formally typeset
A

Allan S. Lieberthal

Researcher at Kaiser Permanente

Publications -  20
Citations -  3544

Allan S. Lieberthal is an academic researcher from Kaiser Permanente. The author has contributed to research in topics: Guideline & Palivizumab. The author has an hindex of 11, co-authored 20 publications receiving 3112 citations. Previous affiliations of Allan S. Lieberthal include American Academy of Pediatrics.

Papers
More filters
Journal ArticleDOI

Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis

TL;DR: This guideline is a revision of the clinical practice guideline, “Diagnosis and Management of Bronchiolitis,” published by the American Academy of Pediatrics in 2006, and indicates level of evidence, benefit-harm relationship, and level of recommendation.
Journal ArticleDOI

Diagnosis and management of bronchiolitis

TL;DR: This guideline addresses the diagnosis of bronchiolitis as well as various therapeutic interventions including bronchodilators, corticosteroids, antiviral and antibacterial agents, hydration, chest physiotherapy, and oxygen.
Journal ArticleDOI

Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

TL;DR: The updated recommendations in this policy statement reflect new information regarding the seasonality of RSV circulation, palivizumab pharmacokinetics, the changing incidence of bronchiolitis hospitalizations, the effect of gestational age and other risk factors on RSV hospitalization rates, the mortality of children hospitalized with RSV infection, the effects of prophylaxis on wheezing, and palivZumab-resistant RSV isolates.
Journal ArticleDOI

Clinical Practice Guideline: Otitis Media with Effusion

TL;DR: The clinical practice guideline on otitis media with effusion (OME) provides evidence-based recommendations on diagnosing and managing OME in children and selected a subcommittee composed of experts in the fields of primary care, otolaryngology, infectious diseases, epidemiology, hearing, speech and language, and advanced practice nursing to revise the OME guideline.